← All trials
NCT04872101
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2021
- Primary completion
- Dec 19, 2022
- Completion date
- Jan 2, 2023
- First posted
- May 4, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Leo PharmaLead sponsor
- Leo PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.